Did fulcrum therapeutics, inc. mislead investors? shareholder rights advocates at levi & korsinsky investigate- fulc

New york, ny / accesswire / september 14, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of fulcrum therapeutics, inc. ("fulcrum therapeutics, inc.") (nasdaq:fulc) concerning possible violations of federal securities laws. fulcrum announced on september 12, 2024, that "its phase 3 reach trial evaluating losmapimod in patients with fshd, did not achieve its primary endpoint of change from baseline in rsa with losmapimod compared to placebo.
FULC Ratings Summary
FULC Quant Ranking